<DOC>
	<DOCNO>NCT01522677</DOCNO>
	<brief_summary>The central hypothesis study safe feasible administer intraluminal photodynamic therapy ( PDT ) colon cancer colonoscopy induce localize inflammatory/immune response . The objective demonstrate feasibility safety PDT colon cancer patient administer surgery characterize inflammatory/immune response tumor site systemically . The long-term objective study modify natural biology colorectal cancer improve patient survival .</brief_summary>
	<brief_title>A Study Neoadjuvant Photodynamic Immunomodulation Colon Cancer</brief_title>
	<detailed_description>The central hypothesis study safe feasible administer intraluminal photodynamic therapy ( PDT ) colon cancer , via colonoscopy , neoadjuvant set induce localize tumor cell death inflammatory/immune response increase Th1 component , utilize 5-ALA photosensitizer . The objective conduct initial phase I/II clinical study demonstrate feasibility safety colonoscopic , neoadjuvant intraluminal PDT colon cancer patient administer 96 hour pre-resection , characterize inflammatory/immune response PDT treat tumor site , evaluate systemic anti-tumor immune response . The long-term objective study provide easily administer , adjunctive , therapeutic maneuver lack systemic toxicity , potential modulate natural biology colorectal cancer elicit favorable anti-tumor immune response improve patient survival .</detailed_description>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Aminolevulinic Acid</mesh_term>
	<criteria>1 . Patients must histologically prove diagnosis colorectal cancer . 2 . Have clinical stage I , II , III disease . 3 . Expected survival must great twelve ( 12 ) month . 4 . A Karnofsky Performance Status ( KPS ) must 70 great ( Appendix I ) . 5 . Patients must &gt; 21 year age . 6 . No prior therapy . 7 . Female patient must lactate must surgically sterile ( via hysterectomy bilateral tubal ligation ) , postmenopausal , use acceptable method contraception child bear potential . Female patient childbearing potential must also negative serum pregnancy test . 8 . Patients must able understand sign inform consent form , must comply U.S. regulation ( U.S. 21 CFR 50 ) ICH guideline . 9 . Eligible patient must adequate initial hematologic coagulation parameter , hemoglobin ≥ 11g/dl , platelet count &gt; 50,000 , Protime Prothrombin Time ≤ 1.5 x normal . 10 . Eligible patient must adequate bone marrow , liver renal function : ANC &gt; 1500/μL , Platelets &gt; 100,000 x μL , total bilirubin &lt; upper limit normal ( ULN ) , creatinine clearance ( CrCl ) &gt; 45 mL/min 1 . Any comorbidity precludes primary surgical resection colorectal tumor . 2 . Any significant general organ system compromise include : Liver function , transaminases ≥ 2 x , Renal function , Cr ≥ 1.5 x upper limit normal Pulmonary function , room air O2 saturation &lt; 90 % Cardiovascular function , Patients significant ( Class III IV ) cardiovascular disease accord New York Heart Association 's functional criterion ( Appendix II ) Gastrointestinal function , i.e . active inflammatory bowel disease active peptic ulcer disease . 3 . Any contraindication repeat colonoscopy , idiosyncratic reactivity conscious sedation medication . 4 . Prior treatment diagnosis colorectal cancer , include surgical resection . 5 . Stage IV colorectal cancer , i.e . clinical presence metastases 6 . Prior malignant diagnosis except basal cell epithelioma skin . 7 . Persistent fever great 38 C. 8 . Mineral overload syndrome Lead , Zinc , Copper Iron . 9 . Use agent modulates 5ALA metabolism porphyrin synthesis , e.g . St. John 's Wort . 10 . Required use corticosteroid immune suppression reason include organ allograft HIV infection 11 . Patients acute chronic illness include cardiovascular disease ( e.g . history atrial fibrillation ventricular arrhythmia ) history myocardial infarction , autoimmune state , psychiatric illness opinion Investigators would compromise treatment . 12 . Use investigational drug within 30 day execution inform consent form .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>tumor immunology</keyword>
	<keyword>neoadjuvant</keyword>
	<keyword>colonoscopy</keyword>
	<keyword>photosensitization</keyword>
</DOC>